Laurion Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Laurion Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-100,000	Closed	-$6.09M	–	799
2019 Q4	$6.09M	Buy	+100,000	New	+$5.46M	0.05%	281
2018 Q4	–	Sell	-172,725	Closed	-$7.66M	–	1160
2018 Q3	$7.66M	Buy	+172,725	New	+$9.05M	0.07%	265
2017 Q4	–	Sell	-67,636	Closed	-$1.21M	–	1578
2017 Q3	$1.21M	Buy	+67,636	New	+$1.23M	0.01%	913
2017 Q1	–	Sell	-26,000	Closed	-$527K	–	1336
2016 Q4	$527K	Buy	+26,000	New	+$486K	0.01%	825

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Laurion Capital Management's CRSP Position: Q1 2020 in Review

Laurion Capital Management sold out of CRISPR Therapeutics (CRSP) in Q1 2020, closing a stake of 100,000 shares — an estimated $6.09M sold.

Laurion Capital Management first reported a position in CRSP in Q4 2016 and held it in 4 quarters. The position peaked at $7.66M in Q3 2018. 257 funds tracked by Wall St. Rank hold CRSP as of Q1 2020.

Laurion Capital Management reported no remaining CRISPR Therapeutics position as of Q1 2020 after selling out during the quarter.
Laurion Capital Management sold 100,000 CRISPR Therapeutics shares in Q1 2020, an estimated $6.09M.
Laurion Capital Management first reported a position in CRISPR Therapeutics in Q4 2016 and held it in 4 quarters.
Laurion Capital Management's CRISPR Therapeutics position peaked at $7.66M in Q3 2018.
257 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2020.

Based on Laurion Capital Management's 13F filing for Q1 2020, filed 14 May 2020.